Matt Seefeldt is VP of CMC at VitriVax and has over twenty years of CMC experience in the protein biologics and cell-therapy space. During his career, he was instrumental in developing or transferring processes for over eleven INDs, and in collaboration with his team, successfully executing over a hundred GMP manufacturing runs. Matt conducted his PhD studies with Dr. Ted Randolph at the University of Colorado where he evaluated the use of high pressure to reduce particle formation and immunogenicity of IFN-beta-1b. His graduate research resulted in a start-up company, BaroFold, where he served as the Chief Scientific Officer. After leaving BaroFold, Matt joined the Gates Biomanufacturing Facility located on the Anschutz Medical Campus in Denver, Colorado as the Executive Director. GBF is a leading academic GMP Phase I facility that routinely manufactures Phase I cell therapy products. Matt guided the GBF organization through the formation of the Gates Institute, with a $200M investment and mission to develop novel cell and gene therapies at the campus. Matt’s experience spans all aspects of process development, manufacturing, qualify control testing, quality systems, and people management – particularly from an operational perspective in the Phase I setting.